Skip to main content
SpringerLink
Log in

Application of Immunohistochemistry in Diagnosis of Renal Cell Neoplasms

  • Chapter
  • First Online:
Kidney Cancer

  • 999 Accesses

Abstract

Renal neoplasms comprise a heterogeneous group of tumors with divergent clinicopathological and molecular characteristics as well as therapeutic options. Therefore, accurate diagnosis and classification of the different subtypes of renal cell carcinoma (RCC), and to verify the renal primary in the setting of metastatic disease are critical for patient management and determining prognosis. In the last three decades, more and more subtypes of RCC have been described and many of them have overlapping clinicomorphologic features. Incorporating diagnostic immunohistochemistry and molecular tests in diagnosis of renal tumors is a critical component of our daily surgical pathology practice. In this chapter, we will discuss the immunohistochemical markers that are commonly used in clinical laboratories. In addition, common diagnostic problems that deserve special attention in the differential diagnosis of major RCC subtypes will also be addressed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Zhou M, Roma A, Magi-Galluzzi C. The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms. Clin Lab Med. 2005;25(2):247–57.

    Article  PubMed  Google Scholar 

  2. Skinnider BF, Amin MA. An immunohistochemical approach to the differential diagnosis of renal tumors. Semin Diagn Pathol. 2005;22(1):51–68.

    Article  PubMed  Google Scholar 

  3. Hammerich KH, Ayala GE, Wheeler TM. Application of immunohistochemistry to the genitourinary system (prostate, urinary bladder, testis, and kidney). Arch Pathol Lab Med. 2008;132(3):432–40.

    PubMed  Google Scholar 

  4. Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med. 2011;135(1):92–109.

    PubMed  Google Scholar 

  5. Shen SS, Truong LD, Scarpelli M, Lopez-Beltran A. Role of immunohistochemistry in diagnosing renal neoplasms: when is it really useful? Arch Pathol Lab Med. 2012;136(4):410–7.

    Article  PubMed  Google Scholar 

  6. Reuter VE, Argani P, Zhou M, Delahunt B, et al. Best practices recommendations in the application of immunohistochemistry in the kidney tumors: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014;38(8):e35–49.

    Article  PubMed  Google Scholar 

  7. Zhou M, Deng FM. The utility of immunohistochemistry in the differential diagnosis of renal cell carcinoma. In: Magi-Galluzzi C, Przybycin G, editors. Genitourinary pathology: practical advances. New York: Springer Science; 2015. p. 383–99.

    Google Scholar 

  8. Deng FM, Zhou M. Molecular genetics and immunohistochemistry of renal tumours: translation into clinical practice. Diagn Histopathol. 2016;22(2):73–9.

    Article  Google Scholar 

  9. Al-Ahmadie HA, Alden D, Fines SW, Gopalan A, Touijer KA, Russo P, et al. Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study. Am J Surg Pathol. 2011;35(7):949–61.

    Article  PubMed  Google Scholar 

  10. Alderman MA, Daignault S, Wolf JS Jr, Palapattu GS, Weizer AZ, et al. Categorizing renal oncocytic neoplasms on core needle biopsy: a morphologic and immunophenotypic study of 144 cases with clinical follow-up. Hum Pathol. 2016;55:1–10.

    Article  PubMed  Google Scholar 

  11. Gupta R, Balzer B, Picken M, Osunkoya AO, Shet T, Alsabeh R, et al. Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms. Am J Surg Pathol. 2009;33(2):241–7.

    Article  PubMed  Google Scholar 

  12. Ozcan A, de la Roza G, Ro JY, Shen SS, Truong LD. PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison. Arch Pathol Lab Med. 2016;136(12):1541–51.

    Article  CAS  Google Scholar 

  13. McGregor DK, Khurana KK, Cao C, Ayala G, Krishnan B, et al. Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody ‘Renal Cell Carcinoma Marker’. Am J Surg Pathol. 2001;25(12):1485–92.

    Article  CAS  PubMed  Google Scholar 

  14. Lin F, Zhang PL, Yang XJ, Shi J, Blasick T, Han WK, et al. Human kidney injury molecule-1 (hKIM-1): a useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma. Am J Surg Pathol. 2007;31(3):371–81.

    Article  PubMed  Google Scholar 

  15. Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol. 2001;158(3):905–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol. 2002;26(7):926–31.

    Article  PubMed  Google Scholar 

  17. Molinie V, Balaton A, Rotman S, Mansouri D, De Pinieux I, Homsi T, et al. Alpha-methyl CoA racemase expression in renal cell carcinomas. Hum Pathol. 2006;37(6):698–703.

    Article  CAS  PubMed  Google Scholar 

  18. Young AN, de Oliveira Salles PG, Lim SD, Cohen C, Petros JA, Marshall FF, et al. Beta defensin-1, parvalbumin, and vimentin: a panel of diagnostic immunohistochemical markers for renal tumors derived from gene expression profiling studies using cDNA microarrays. Am J Surg Pathol. 2003;27(2):199–205.

    Article  PubMed  Google Scholar 

  19. Shen SS, Krishna B, Chirala R, Amato RJ, Truong LD. Kidney-specific cadherin, a specific marker for the distal portion of the nephron and related renal neoplasms. Mod Pathol. 2005;18(7):933–40.

    Article  CAS  PubMed  Google Scholar 

  20. Huo L, Sugimura J, Tretiakova MS, Patton KT, Gupta R, Popov B, et al. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas. Hum Pathol. 2005;36(3):262–8.

    Article  CAS  PubMed  Google Scholar 

  21. Castillo M, Petit A, Mellado B, Palacín A, Alcover JB, Mallofré C. C-kit expression in sarcomatoid renal cell carcinoma: potential therapy with imatinib. J Urol. 2004;171(6 Pt 1):2176–80.

    Article  CAS  PubMed  Google Scholar 

  22. Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003;27(6):750–61.

    Article  PubMed  Google Scholar 

  23. Argani P, Lae M, Hutchinson B, Reuter VE, Collins MH, Perentesis J, et al. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol. 2005;29(2):230–40.

    Article  PubMed  Google Scholar 

  24. Camparo P, Vasiliu V, Molinie V, Couturier J, Dykema KJ, Petillo D, et al. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol. 2008;32(5):656–70.

    Article  PubMed  Google Scholar 

  25. Martignoni G, Pea M, Gobbo S, Brunelli M, Bonetti F, Segala D, et al. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod Pathol. 2009;22(8):1016–22.

    Article  CAS  PubMed  Google Scholar 

  26. Martignoni G, Bonetti F, Chilosi M, Brunelli M, Segala D, Amin MB, et al. Cathepsin K expression in the spectrum of perivascular epithelioid cell (PEC) lesions of the kidney. Mod Pathol. 2012;25(1):100–11.

    Article  CAS  PubMed  Google Scholar 

  27. Albadine R, Schultz L, Illei P, Ertoy D, Hicks J, Sharma R, et al. PAX8 (+)/p63 (−) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract. Am J Surg Pathol. 2010;34(7):965–9.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Trpkov K, Abou-Ouf H, Hes O, Lopez JI, Nesi G, Comperat E, et al. Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC): further morphologic and molecular characterization of ESC RCC as a distinct entity. Am J Surg Pathol. 2017;41(10):1299–308.

    Article  PubMed  Google Scholar 

  29. Palsgrove DN, Li Y, Pratilas C, Lin MT, Pallavajjalla A, Gocke C, et al. Eosinophilic Solid and Cystic (ESC) renal cell carcinomas harbor TSC mutations: molecular analysis supports an expanding clinicopathologic spectrum. Am J Surg Pathol. 2018; https://doi.org/10.1097/PAS.0000000000001111.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Choueiri TK, Cheville J, Palescandolo E, Fay AP, Kantoff PW, Atkins MB, et al. BRAF mutations in metanephric adenoma of the kidney. Eur Urol. 2012;62(5):91722.

    Article  CAS  Google Scholar 

  31. Kinney SN, Eble JN, Hes O, Williamson SR, Grignon DJ, Wang M, et al. Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma. Mod Pathol. 2015;28(9):1236–48.

    Article  CAS  PubMed  Google Scholar 

  32. Ohe C, Smith SC, Sirohi D, Divatia M, de Peralta-Venturina M, Paner GP, et al. Reappraisal of morphologic differences between renal medullary carcinoma, collecting duct carcinoma, and fumarate hydratase-deficient renal cell carcinoma. Am J Surg Pathol. 2018;42(3):279–92.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Rao P, Tannir NM, Tamboli P. Expression of OCT3/4 in renal medullary carcinoma represents a potential diagnostic pitfall. Am J Surg Pathol. 2012;36(4):583–8.

    Article  PubMed  Google Scholar 

  34. Chen YB, Brannon AR, Toubaji A, Dudas ME, Won HH, Al-Ahmadie HA, et al. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. Am J Surg Pathol. 2014;38(5):627–37.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Gill AJ, Pachter NS, Clarkson A, Tucker KM, Winship IM, Benn DE, et al. Renal tumors and hereditary pheochromocytoma-paraganglioma syndrome type 4. N Engl J Med. 2011;364:885–6.

    Article  CAS  PubMed  Google Scholar 

  36. Gill AJ, Hes O, Papathomas T, Šedivcová M, Tan PH, Agaimy A, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol. 2014;38(12):1588–602.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Li Y, Reuter VE, Matoso A, Netto GJ, Epstein JI, Argani P. Re-evaluation of 33 ‘unclassified’ eosinophilic renal cell carcinomas in young patients. Histopathology. 2018;72(4):588–600.

    Article  PubMed  Google Scholar 

  38. Deng FM, Kong M, Zhou M. Papillary or pseudopapillary tumors of the kidney. Semin Diagn Pathol. 2015;32:124–39.

    Article  PubMed  Google Scholar 

  39. Aydin H, Chen L, Cheng L, Vaziri S, He H, Ganapathi R, et al. Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney. Am J Surg Pathol. 2010;34(11):1608–21.

    PubMed  Google Scholar 

  40. Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005;11(10):3714–21.

    Article  CAS  PubMed  Google Scholar 

  41. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol. 2010;58(1):75–83.

    Article  CAS  PubMed  Google Scholar 

  42. Choueiri TK, Regan MM, Rosenberg JE, et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int. 2010;106:772–8.

    Article  CAS  PubMed  Google Scholar 

  43. TK C, Cheng S, Qu AQ, Pastorek J, Atkins MB, Signoretti S. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). Urol Oncol. 2013;8:1788–93.

    Google Scholar 

  44. Jiang Z, Chu PG, Kang Y, Lee SS. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 2006;7(7):556–64.

    Article  CAS  PubMed  Google Scholar 

  45. Hakimi AA, Chen YB, Wren J, Gonen M, Abdel-Wahab O, Heguy A, et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol. 2013;63(5):848–54.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, New York University Langone Medical Health, New York, NY, USA

    Fang-Ming Deng

  2. Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL, USA

    Qihui Jim Zhai

Authors
  1. Fang-Ming Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qihui Jim Zhai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fang-Ming Deng .

Editor information

Editors and Affiliations

  1. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Medical College of Cornell University, Houston, TX, USA

    Mukul K. Divatia

  2. Gulhane Military Medical Academy, School of Medicine, Department of Pathology, Ankara, Turkey

    Ayhan Ozcan

  3. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Charles C. Guo

  4. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Medical College of Cornell University, Houston, TX, USA

    Jae Y. Ro

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Deng, FM., Zhai, Q.J. (2020). Application of Immunohistochemistry in Diagnosis of Renal Cell Neoplasms. In: Divatia, M., Ozcan, A., Guo, C., Ro, J. (eds) Kidney Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-28333-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-28333-9_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-28332-2

  • Online ISBN: 978-3-030-28333-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation